Journal profile · Medicine-Pharmacology (medical)
Infection and Drug Resistance
ISSN 1178-6973 · Dove Medical Press Ltd. · UNITED STATES
Infection and Drug Resistance: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.16; JCR Q2 (journal website); fully open access; APC about USD 4,320; median 80 days to acceptance (137 articles, last 24 months); acceptance rate 21% (journal website); 599 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Infection and Drug Resistance is published by Dove Medical Press Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Resistance in Bacteria, Tuberculosis Research and Epidemiology and Bacterial Identification and Susceptibility Testing, together about 29.8% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Oliver Planz Infection and Drug Resistance is an international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal, viral and parasitic) and the development and institution of preventative strategies to minimize the development and spread of resistance. The journal is characterized by the rapid reporting of high-quality original research, reviews, guidelines, expert opinions, commentary and clinical studies in all areas of infection and drug resistance. Infection and Drug Resistance will no longer consider meta-analyses for publication. Specific topics covered by the journal include: Development of novel anti-infectives Optimal use of existing anti-infectives Pathogenesis and etiology of infectious disease Proteomic and genomic studies in resistant organisms Mechanisms of resistance development Vaccine development and implementation Infection control in hospitals and the community Diagnosis and early detection of infection Clinical management of infection Clinical management of antibiotic resistance (e.g. in transplant and HIV patients) Epidemiology of infection and antibiotic resistance Education and prevention of drug resistance Patient adherence and satisfaction The journal does not accept study protocols. The journal will consider case reports only if they make a valuable and original contribution to the literature. When considering submission of a paper utilizing publicly available data authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample. Updated 17 July 2025
From the journal's Aims & Scope
Research area (LetPub): Medicine-Pharmacology (medical)
Editor-in-chief Oliver PlanzPublisher website
Editorial board by country: 13 in mainland China (about 18%); most named United States 17, Mainland China 13, India 6, Italy 6, United Kingdom 5 (72 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology17.2%
- Tuberculosis Research and EpidemiologyMedicine6.4%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology6.2%
- Antibiotic Use and ResistanceImmunology and Microbiology5.9%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.4%
- Nosocomial Infections in ICUMedicine5.1%
- Antimicrobial Resistance in StaphylococcusMedicine4.8%
- Pneumonia and Respiratory InfectionsMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.16LetPub ·
- Impact factor (publisher) 2025
- 3.5Publisher website ·
- 5-year impact factor (publisher)
- 5.6Publisher website ·
- CiteScore 2026-06
- 5.6LetPub ·
- CiteScore (publisher) 2025
- 1.06Publisher website ·
- SJR 2026-06
- 0.79LetPub ·
- SNIP 2026-06
- 1.06LetPub ·
- h-index
- 27LetPub ·
- h-index
- 96OpenAlex ·
- i10-index
- 2,177OpenAlex ·
- 2-year mean citedness
- 2.82OpenAlex ·
- Self-citation rate
- 6.2%LetPub ·
- Share of gold OA articles
- 99.5%LetPub ·
Volume
- Articles per year
- 594LetPub ·
- Downloads per year (publisher)
- 672,342Publisher website ·
Articles by year OpenAlex count · 5,106 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 550 | 550 | 151 |
| 2025 | 599 | 599 | 1,725 |
| 2024 | 563 | 563 | 2,946 |
| 2023 | 705 | 705 | 8,078 |
| 2022 | 735 | 735 | 10,164 |
| 2021 | 551 | 551 | 12,266 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
80 daysMedian, submission to acceptance · P25–P75 65 days – 99 days
- Acceptance to online
- median 15 days (137 articles)
- Submission to online
- median 97 days
- Sample
- 137 articles with submission and acceptance dates (1,307 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- Desk decision
- 46 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- original researchOriginal ResearchLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press Ltd.
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 1178-6973
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Infection and Drug Resistance
What CAS zone is Infection and Drug Resistance in?
In the 2025 upgraded edition of the CAS Journal Ranking, Infection and Drug Resistance is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy / Infectious Diseases. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Infection and Drug Resistance?
The latest impact factor listed by LetPub is 3.16; CiteScore 5.6, h-index 96.
How long does peer review take at Infection and Drug Resistance?
Based on the dates recorded on 137 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 80 days (interquartile range 65–99 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 21%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Infection and Drug Resistance in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Infection and Drug Resistance based?
Of the 72 board members whose country the journal's board page names, 13 (about 18%) are in mainland China; the countries named most often are United States (17), Mainland China (13) and India (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Infection and Drug Resistance?
According to LetPub and DOAJ records, Infection and Drug Resistance is indexed in SCIE, Scopus and DOAJ.
Is Infection and Drug Resistance open access, and what is the APC?
Infection and Drug Resistance is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .